Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Non-Current Assets (2018 - 2025)

Historic Non-Current Assets for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $2.9 million.

  • ImmunoTech's Non-Current Assets fell 5149.55% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 3302.18%. This contributed to the annual value of $4.4 million for FY2024, which is 814.51% down from last year.
  • ImmunoTech's Non-Current Assets amounted to $2.9 million in Q3 2025, which was down 5149.55% from $3.1 million recorded in Q2 2025.
  • ImmunoTech's Non-Current Assets' 5-year high stood at $6.0 million during Q3 2024, with a 5-year trough of $2.9 million in Q3 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $4.8 million (2023), whereas its average is $4.5 million.
  • As far as peak fluctuations go, ImmunoTech's Non-Current Assets skyrocketed by 1756.2% in 2024, and later plummeted by 5149.55% in 2025.
  • Over the past 3 years, ImmunoTech's Non-Current Assets (Quarter) stood at $4.8 million in 2023, then decreased by 8.15% to $4.4 million in 2024, then plummeted by 34.14% to $2.9 million in 2025.
  • Its Non-Current Assets was $2.9 million in Q3 2025, compared to $3.1 million in Q2 2025 and $3.7 million in Q1 2025.